Preclinical and clinical evidence of antioxidant effects of antidepressant agents: Implications for the pathophysiology of major depressive disorder

Oxidative Medicine and Cellular Longevity

Volumn , Issue , 2012, Pages

  Behr, Guilherme A ^a,b   Moreira, José C F ^b   Frey, Benicio N ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL MODEL; ANTIDEPRESSANT DRUG; ANTIOXIDANT DEFENCE; ANTIOXIDANT EFFECT; ANTIOXIDANT POTENTIAL; COGNITIVE FUNCTIONS; DATA SUPPORT; DEPRESSIVE SYMPTOM; ELEVATED LEVEL; HEALTHY CONTROLS; IN-VITRO; ISOPROSTANES; MECHANISM OF ACTION; MENTAL DISORDERS; NEUROPROTECTIVE EFFECTS; PATHOPHYSIOLOGY; QUALITY OF LIFE; URINARY EXCRETION;

HEALTH CARE; MEDICINE;

CELL CULTURE;

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CASPASE 3; CITALOPRAM; CYTOCHROME C; DESIPRAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GINKGO BILOBA EXTRACT; IMIPRAMINE; INTERLEUKIN 6; MALONALDEHYDE; MAPROTILINE; MILNACIPRAN; MIRTAZAPINE; MOCLOBEMIDE; NEFAZODONE; NITRIC OXIDE; NORTRIPTYLINE; PAROXETINE; REBOXETINE; SERTRALINE; SUPEROXIDE DISMUTASE; TIANEPTINE; TRAZODONE; UNINDEXED DRUG; VENLAFAXINE; ANTIOXIDANT;

ANTIOXIDANT ACTIVITY; CELL DEATH; COGNITION; DISEASE SEVERITY; DNA DAMAGE; DNA FRAGMENTATION; DRUG DEVELOPMENT; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; DRUG SCREENING; ELECTRON TRANSPORT; ENERGY METABOLISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME RELEASE; ENZYME SYNTHESIS; FOLLOW UP; FORCED SWIMMING TEST; HIPPOCAMPUS; HUMAN; IMMUNE SYSTEM; IN VITRO STUDY; LONG TERM CARE; MAJOR DEPRESSION; MITOCHONDRIAL MEMBRANE POTENTIAL; MORBIDITY; MORTALITY; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PREMEDICATION; PYRAMIDAL NERVE CELL; QUALITY OF LIFE; RESPIRATORY CHAIN; REVIEW; SIGNAL TRANSDUCTION; TREATMENT DURATION; ANIMAL; BRAIN; CLINICAL TRIAL (TOPIC); DISEASE MODEL; PATHOLOGY;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIOXIDANTS; BRAIN; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER, MAJOR; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; OXIDATIVE STRESS;

EID: 84862287737     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2012/609421     Document Type: Review

References (68)

1. Castrén E., Is mood chemistry? Nature Reviews Neuroscience 2005 6 3 241 246 (Pubitemid 40342418)
2. Imlay J. A., Cellular defenses against superoxide and hydrogen peroxide Annual Review of Biochemistry 2008 77 755 776
3. Harwell B., Biochemistry of oxidative stress Biochemical Society Transactions 2007 35 5 1147 1150 (Pubitemid 350206447)
4. Valko M., Leibfritz D., Moncol J., Cronin M. T. D., Mazur M., Telser J., Free radicals and antioxidants in normal physiological functions and human disease International Journal of Biochemistry and Cell Biology 2007 39 1 44 84 (Pubitemid 44566469)
5. Halliwell B., Oxidative stress and neurodegeneration: where are we now? Journal of Neurochemistry 2006 97 6 1634 1658 (Pubitemid 43873658)
6. Curti C., Mingatto F. E., Polizello A. C. M., Galastri L. O., Uyemura S. A., Santos A. C., Fluoxetine interacts with the lipid bilayer of the inner membrane in isolated rat brain mitochondria, inhibiting electron transport and F1F0-ATPase activity Molecular and Cellular Biochemistry 1999 199 1-2 103 109 (Pubitemid 29476148)
7. Souza M. E. J., Polizello A. C. M., Uyemura S. A., Castro-Silva O., Curti C., Effect of fluoxetine on rat liver mitochondria Biochemical Pharmacology 1994 48 3 535 541 (Pubitemid 24257016)
8. Nahon E., Israelson A., Abu-Hamad S., Shoshan-Barmatz V., Fluoxetine (Prozac) interaction with the mitochondrial voltage-dependent anion channel and protection against apoptotic cell death FEBS Letters 2005 579 22 5105 5110 (Pubitemid 41242861)
9. Zhang W. H., Wang H., Wang X., Narayanan M. V., Stavrovskaya I. G., Kristal B. S., Friedlander R. M., Nortriptyline protects mitochondria and reduces cerebral ischemia/hypoxia injury Stroke 2008 39 2 455 462 (Pubitemid 351619471)
10. Kolla N., Wei Z., Richardson J. S., Li X. M., Amitriptyline and fluoxetine protect PC12 cells from cell death induced by hydrogen peroxide Journal of Psychiatry and Neuroscience 2005 30 3 196 201 (Pubitemid 40942458)
11. Hashioka S., Klegeris A., Monji A., Kato T., Sawada M., McGeer P. L., Kanba S., Antidepressants inhibit interferon- -induced microglial production of IL-6 and nitric oxide Experimental Neurology 2007 206 1 33 42 (Pubitemid 46935120)
12. Schmidt A. J., Heiser P., Hemmeter U. M., Krieg J. C., Vedder H., Effects of antidepressants on mRNA levels of antioxidant enzymes in human monocytic U-937 cells Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008 32 6 1567 1573
13. Dhir A., Kulkarni S. K., Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor European Journal of Pharmacology 2007 568 13 177 185 (Pubitemid 46976903)
14. Zomkowski A. D. E., Engel D., Gabilan N. H., Rodrigues A. L. S., Involvement of NMDA receptors and l-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effects of escitalopram in the forced swimming test European Neuropsychopharmacology 2010 20 11 793 801
15. Krass M., Wegener G., Vasar E., Volke V., The antidepressant action of imipramine and venlafaxine involves suppression of nitric oxide synthesis Behavioural Brain Research 2011 218 1 57 63
16. Vismari L., Alves G. J., Muscar M. N., Palermo-Neto J., A possible role to nitric oxide in the anti-inflammatory effects of amitriptyline. Immunopharmacology and Immunotoxicology. In press
17. Réus G. Z., Stringari R. B., De Souza B., Petronilho F., Dal-Pizzol F., Hallak J. E., Zuardi A. W., Crippa J. A., Quevedo J., Harmine and imipramine promote antioxidant activities in prefrontal cortex and hippocampus Oxidative Medicine and Cellular Longevity 2010 3 5 325 331
18. Reus G. Z., Stringari R. B., Gonalves C. L., Administration of harmine and imipramine alters creatine kinase and mitochondrial respiratory chain activities in the rat brain Depression Research and Treatment 2012 2012 7
19. Lobato K. R., Cardoso C. C., Binfaré R. W., Budni J., Wagner C. L. R., Brocardo P. S., de Souza L. F., Brocardo C., Flesch S., Freitas A. E., Dafré A. L., Rodrigues A. L. S., -Tocopherol administration produces an antidepressant-like effect in predictive animal models of depression Behavioural Brain Research 2010 209 2 249 259
20. Katyare S. S., Rajan R. R., Effect of long-term in vivo treatment with imipramine on the oxidative energy metabolism in rat brain mitochondria Comparative Biochemistry and Physiology Part C 1995 112 3 353 357 (Pubitemid 26038873)
21. Xu H., Steven Richardson J., Li X. M., Dose-related effects of chronic antidepressants on neuroprotective proteins BDNF, Bcl-2 and Cu/Zn-SOD in rat hippocampus Neuropsychopharmacology 2003 28 1 53 62
22. Inkielewicz-Stpniak I., Impact of fluoxetine on liver damage in rats Pharmacological Reports 2011 63 2 441 447
23. Novio S., Nez M. J., Amigo G., Freire-Garabal M., Effects of fluoxetine on the oxidative status of peripheral blood leucocytes of restraint-stressed mice Basic Clinical Pharmacology Toxicology 2011 109 5 365 371
24. Zafir A., Ara A., Banu N., In vivo antioxidant status: a putative target of antidepressant action Progress in Neuro-Psychopharmacology and Biological Psychiatry 2009 33 2 220 228
25. Djordjevic J., Djordjevic A., Adzic M., Elakovi I., Mati G., Radojcic M. B., Fluoxetine affects antioxidant system and promotes apoptotic signaling in Wistar rat liver European Journal of Pharmacology 2011 659 1 61 66
26. Abdel-Wahab B. A., Salama R. H., Venlafaxine protects against stress-induced oxidative DNA damage in hippocampus during antidepressant testing in mice Pharmacology Biochemistry and Behavior 2011 100 1 59 65
27. Khanzode S. D., Dakhale G. N., Khanzode S. S., Saoji A., Palasodkar R., Oxidative damage and major depression: the potential antioxidant action of selective serotonin-re-uptake inhibitors Redox Report 2003 8 6 365 370 (Pubitemid 38128544)
28. Sarandol A., Sarandol E., Eker S. S., Erdinc S., Vatansever E., Kirli S., Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidativeantioxidative systems Human Psychopharmacology 2007 22 2 67 73 (Pubitemid 46505714)
29. Herken H., Gurel A., Selek S., Armutcu F., Ozen M. E., Bulut M., Kap O., Yumru M., Savas H. A., Akyol O., Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: impact of antidepressant treatment Archives of Medical Research 2007 38 2 247 252 (Pubitemid 46080553)
30. Bilici M., Efe H., Krolu M. A., Uydu H. A., Bekarolu M., Deer O., Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments Journal of Affective Disorders 2001 64 1 43 51 (Pubitemid 32268670)
31. Gawryluk J. W., Wang J. F., Andreazza A. C., Shao L., Young L. T., Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders International Journal of Neuropsychopharmacology 2011 14 1 123 130
32. Cumurcu B. E., Ozyurt H., Etikan I., Demir S., Karlidag R., Total antioxidant capacity and total oxidant status in patients with major depression: impact of antidepressant treatment Psychiatry and Clinical Neurosciences 2009 63 5 639 645
33. Kotan V. O., Sarandol E., Kirhan E., Ozkaya G., Kirli S., Effects of long-term antidepressant treatment on oxidative status in major depressive disorder: a 24-week follow-up study Progress in Neuro-Psychopharmacology and Biological Psychiatry 2011 35 5 1284 1290
34. Maes M., Mihaylova I., Kubera M., Uytterhoeven M., Vrydags N., Bosmans E., Lower plasma Coenzyme Q10 in depression: a marker for treatment resistance and chronic fatigue in depression and a risk factor to cardiovascular disorder in that illness Neuroendocrinology Letters 2009 30 4 462 469
35. Michel T. M., Camara S., Tatschner T., Frangou S., Sheldrick A. J., Riederer P., Grnblatt E., Increased xanthine oxidase in the thalamus and putamen in depression World Journal of Biological Psychiatry 2010 11 2 314 320
36. Gawryluk J. W., Wang J. F., Andreazza A. C., Shao L., Yatham L. N., Young L. T., Prefrontal cortex glutathione S-transferase levels in patients with bipolar disorder, major depression and schizophrenia The International Journal of Neuropsychopharmacology 2011 14 8 1069 1074
37. Halliwell B., Free radicals and antioxidantsquo vadis? Trends in Pharmacological Sciences 2011 32 3 125 130
38. Janero D. R., Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury Free Radical Biology and Medicine 1990 9 6 515 540 (Pubitemid 120036914)
39. Del Rio D., Stewart A. J., Pellegrini N., A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress Nutrition, Metabolism and Cardiovascular Diseases 2005 15 4 316 328 (Pubitemid 41190990)
40. Zarkovic N., 4-Hydroxynonenal as a bioactive marker of pathophysiological processes Molecular Aspects of Medicine 2003 24 4-5 281 291 (Pubitemid 36945028)
41. Halliwell B., Lee C. Y. J., Using isoprostanes as biomarkers of oxidative stress: some rarely considered issues Antioxidants and Redox Signaling 2010 13 2 145 156
42. Dalle-Donne I., Rossi R., Giustarini D., Milzani A., Colombo R., Protein carbonyl groups as biomarkers of oxidative stress Clinica Chimica Acta 2003 329 1-2 23 38 (Pubitemid 36187411)
43. Ellman G. L., Tissue sulfhydryl groups Archives of Biochemistry and Biophysics 1959 82 1 70 77
44. Young I. S., Measurement of total antioxidant capacity Journal of Clinical Pathology 2001 54 5 339 (Pubitemid 32458129)
45. Coyle J. T., Puttfarcken P., Oxidative stress, glutamate, and neurodegenerative disorders Science 1993 262 5134 689 695 (Pubitemid 23350687)
46. Gardner A., Boles R. G., Beyond the serotonin hypothesis: mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders Progress in Neuro-Psychopharmacology and Biological Psychiatry 2011 35 3 730 743
47. Chopra K., Kumar B., Kuhad A., Pathobiological targets of depression Expert Opinion on Therapeutic Targets 2011 15 4 379 400
48. Gaecki P., Szemraj J., Biekiewicz M., Florkowski A., Gaecka E., Lipid peroxidation and antioxidant protection in patients during acute depressive episodes and in remission after fluoxetine treatment Pharmacological Reports 2009 61 3 436 447
49. Harrison R., Physiological roles of xanthine oxidoreductase Drug Metabolism Reviews 2004 36 2 363 375 (Pubitemid 38802492)
50. Dimopoulos N., Piperi C., Psarra V., Lea R. W., Kalofoutis A., Increased plasma levels of 8-iso-PGF2 and IL-6 in an elderly population with depression Psychiatry Research 2008 161 1 59 66
51. Pratic D., Rokach J., Lawson J., FitzGerald G. A., F2-isoprostanes as indices of lipid peroxidation in inflammatory diseases Chemistry and Physics of Lipids 2004 128 1-2 165 171 (Pubitemid 38167385)
52. Maes M., Mihaylova I., Kubera M., Uytterhoeven M., Vrydags N., Bosmans E., Increased 8-hydroxy-deoxyguanosine, a marker of oxidative damage to DNA, in major depression and myalgic encephalomyelitis/chronic fatigue syndrome Neuroendocrinology Letters 2009 30 6 715 722
53. Reus G. Z., Stringari R. B., Rezin G. T., Administration of memantine and imipramine alters mitochondrial respiratory chain and creatine kinase activities in rat brain Journal of Neural Transmission 2012 119 4 481 491
54. Rojas P., Serrano-Garca N., Medina-Campos O. N., Pedraza-Chaverri J., gren S. O., Rojas C., Antidepressant-like effect of a Ginkgo biloba extract (EGb761) in the mouse forced swimming test: role of oxidative stress Neurochemistry International 2011 59 5 628 638
55. Zhao Z., Wang W., Guo H., Zhou D., Antidepressant-like effect of liquiritin from Glycyrrhiza uralensis in chronic variable stress induced depression model rats Behavioural Brain Research 2008 194 1 108 113
56. Satoh T., Ishige K., Sagara Y., Protective effects on neuronal cells of mouse afforded by ebselen against oxidative stress at multiple steps Neuroscience Letters 2004 371 1 1 5 (Pubitemid 39410504)
57. Posser T., Kaster M. P., Barana S. C., Rocha J. B. T., Rodrigues A. L. S., Leal R. B., Antidepressant-like effect of the organoselenium compound ebselen in mice: evidence for the involvement of the monoaminergic system European Journal of Pharmacology 2009 602 1 85 91
58. Stockmeier C. A., Mahajan G. J., Konick L. C., Overholser J. C., Jurjus G. J., Meltzer H. Y., Uylings H. B. M., Friedman L., Rajkowska G., Cellular changes in the postmortem hippocampus in major depression Biological Psychiatry 2004 56 9 640 650 (Pubitemid 39446845)
59. Zou K., Deng W., Li T., Zhang B., Jiang L., Huang C., Sun X., Sun X., Changes of brain morphometry in first-episode, drug-Nave, non-late-life adult patients with major depression: an optimized voxel-based morphometry study Biological Psychiatry 2010 67 2 186 188
60. Campbell S., MacQueen G., An update on regional brain volume differences associated with mood disorders Current Opinion in Psychiatry 2006 19 1 25 33 (Pubitemid 44406141)
61. Kumar A., Bilker W., Jin Z., Udupa J., Atrophy and high intensity lesions: complementary neurobiological mechanisms in late-life major depression Neuropsychopharmacology 2000 22 3 264 274 (Pubitemid 30089537)
62. Olesen P. J., Gustafson D. R., Simoni M., Pantoni L., Stling S., Guo X., Skoog I., Temporal lobe atrophy and white matter lesions are related to major depression over 5 years in the elderly Neuropsychopharmacology 2010 35 13 2638 2645
63. Maes M., Ruckoanich P., Chang Y. S., Mahanonda N., Berk M., Multiple aberrations in shared inflammatory and oxidative nitrosative stress (IONS) pathways explain the co-association of depression and cardiovascular disorder (CVD), and the increased risk for CVD and due mortality in depressed patients Progress in Neuro-Psychopharmacology and Biological Psychiatry 2011 35 3 769 783
64. Maes M., Galecki P., Chang Y. S., Berk M., A review on the oxidative and nitrosative stress (ONS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness Progress in Neuro-Psychopharmacology and Biological Psychiatry 2011 35 3 676 692
65. Teyssier J. R., Ragot S., Chauvet-Gélinier J. C., Trojak B., Bonin B., Expression of oxidative stress-response genes is not activated in the prefrontal cortex of patients with depressive disorder Psychiatry Research 2011 186 2-3 244 247
66. Frey B. N., Zunta-Soares G. B., Caetano S. C., Nicoletti M. A., Hatch J. P., Brambilla P., Mallinger A. G., Soares J. C., Illness duration and total brain gray matter in bipolar disorder: evidence for neurodegeneration? European Neuropsychopharmacology 2008 18 10 717 722
67. Minuzzi L., Behr G. A., Moreira J. C. F., Frey B. N., Mitochondrial dysfunction in bipolar disorder: lessons from brain imaging and molecular markers Revista Colombiana de Psiquiatra 2011 40 166 182
68. Kapczinski F., Dal-Pizzol F., Teixeira A. L., Magalhaes P. V. S., Kauer-Sant'Anna M., Klamt F., De Bittencourt Pasquali M. A., Quevedo J., Gama C. S., Post R., A systemic toxicity index developed to assess peripheral changes in mood episodes Molecular Psychiatry 2010 15 8 784 786